Reply to: "Can sorafenib use influence outcome when comparing stereotactic body radiation therapy with radiofrequency ablation in patients with hepatocellular carcinoma?"
- PMID: 32467075
- DOI: 10.1016/j.jhep.2020.04.016
Reply to: "Can sorafenib use influence outcome when comparing stereotactic body radiation therapy with radiofrequency ablation in patients with hepatocellular carcinoma?"
Conflict of interest statement
Conflicts of interest The authors declare no conflicts of interest that pertain to this work. Please refer to the accompanying ICMJE disclosure forms for further details.
Comment on
-
Stereotactic body radiation therapy vs. radiofrequency ablation in Asian patients with hepatocellular carcinoma.J Hepatol. 2020 Jul;73(1):121-129. doi: 10.1016/j.jhep.2020.03.005. Epub 2020 Mar 10. J Hepatol. 2020. PMID: 32165253
-
Can sorafenib use influence outcome when comparing stereotactic body radiation therapy with radiofrequency ablation in patients with hepatocellular carcinoma?J Hepatol. 2020 Aug;73(2):467-468. doi: 10.1016/j.jhep.2020.03.016. Epub 2020 May 11. J Hepatol. 2020. PMID: 32409208 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
